The INSIGNIA-PAH is a phase 2/phase 3 study that aimed to assess the efficacy and safety of an inhaled sGC stimulator (MK-5475-007) in PAH (NCT04732221). The gene discussed is SGCB; the disease is pulmonary arterial hypertension.